+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 169 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating whether calderasib combined with subcutaneous pembrolizumab can better treat non-small cell lung cancer NSCLC with the KRAS G12C mutation. The study compares this combination to pembrolizumab with chemotherapy to see if it helps patients live longer without their cancer growing or spreading. This is a phase 3 clinical trial assessing treatment effectiveness and safety in participants with advanced or metastatic nonsquamous NSCLC. Participants will be randomly assigned to one of two groups. One group receives pembrolizumab plus berahyaluronidase alfa as a subcutaneous injection every 6 weeks for up to 18 cycles about 2 years, along with calderasib tablets until treatment discontinuation. The other group receives pembrolizumab plus berahyaluronidase alfa with chemotherapy drugs pemetrexed and either carboplatin or cisplatin given intravenously on specified days in the first cycles, also until discontinuation criteria are met. During the study, participants will have regular assessments including tumor scans and health questionnaires to monitor progression free survival, overall survival, response rates, and quality of life. Adverse events and treatment tolerability will also be tracked up to approximately 81 months. The study aims to provide detailed information on the impact of these treatments on cancer progression and patient well-being over time.

Age: 18Years +All GendersPhase 3
221 locations
P

Actively Recruiting

Researchers are evaluating the safety, tolerability, and pharmacokinetics of SHR-4685 in adults with advanced solid tumors. This phase I study aims to determine the dose-limiting toxicity, maximum tolerated dose, and recommended phase II dose of SHR-4685, helping to understand how the drug behaves in the body and its potential side effects. Participants will receive SHR-4685 in varying doses as part of a single treatment group. The study monitors participants for up to 24 months to assess adverse events, serious adverse events, and drug concentration levels in plasma. The treatment period includes regular assessments at predefined intervals to gather detailed pharmacokinetic data and observe tumor response measures. During the study, participants will undergo evaluations including tumor measurements based on RECIST 1.1 criteria, laboratory tests to monitor organ function and presence of antibodies against SHR-4685, and safety assessments to track side effects. Researchers will measure outcomes such as objective response rate, disease control rate, duration of response, and progression-free survival. Safety monitoring continues for 30 days after the last dose, and the total participation can last up to two years.

Age: 18Years - 75YearsAll GendersPhase 1
6 locations
P

Actively Recruiting

Researchers are investigating the effects of an experimental drug called BNT323 also known as DB-1303 compared with standard chemotherapy in women with recurrent endometrial cancer that expresses the HER2 protein. This Phase III study includes two groups based on HER2 levels one group with lower HER2 expression 1 or 2 who have previously received immune checkpoint inhibitors, and another with higher HER2 expression 3. The study aims to evaluate how well these treatments control the cancer and their safety profiles. Participants in Cohort 1 will be randomly assigned to receive either BNT323 or a chemotherapy drug chosen by their doctor, such as doxorubicin or paclitaxel or docetaxel if paclitaxel is unsuitable. Cohort 2 participants will receive BNT323 alone. Treatments are given through intravenous infusions and continue until the cancer progresses, unacceptable side effects occur, or consent is withdrawn. The study includes screening, treatment lasting about six months, and long-term follow-up for up to 53 months to monitor survival and other outcomes. During the trial, participants will undergo various assessments including imaging scans to measure tumor size, evaluations of side effects, blood tests to study drug behavior and immune responses, and quality of life questionnaires. Safety follow-up occurs shortly after treatment ends, followed by extended monitoring for treatment effectiveness and survival. Participants are closely observed throughout to understand how well BNT323 works compared to chemotherapy and its impact on health and wellbeing.

Age: 18Years +FEMALEPhase 3
206 locations
S

Actively Recruiting

Researchers are evaluating new treatment options for people with locally advanced, unresected non-small cell lung cancer NSCLC that has a KRAS G12C gene mutation. This trial aims to learn if combining calderasib MK-1084 with durvalumab, an immunotherapy, after chemotherapy and radiation can help patients live longer without their cancer growing or spreading. Participants will be randomly assigned to receive either calderasib along with durvalumab or a placebo with durvalumab. Calderasib is taken as an oral tablet, while durvalumab is given by intravenous infusion. The study is blinded so neither participants nor researchers know who receives the active drug or placebo during treatment. During the study, participants will be monitored regularly to assess cancer progression, survival, quality of life, and side effects. This includes tumor testing, blood work, and questionnaires over up to approximately 6 years for progression-free survival and up to 9 years for overall survival and other health measures. The study is sponsored by Merck Sharp & Dohme LLC and follows participants from screening through long-term follow-up.

Age: 18Years +All GendersPhase 3
107 locations
P

Actively Recruiting

Researchers are evaluating new treatments for people with locally advanced or metastatic urothelial cancer UC that has worsened after previous therapies. This phase 3 trial aims to find out if sacituzumab tirumotecan sac-TMT, an investigational drug given by intravenous infusion, can help patients live longer compared to standard non-platinum chemotherapy options. The study is sponsored by Merck Sharp & Dohme LLC. Participants are randomly assigned to receive either sacituzumab tirumotecan at 4 mgkg every two weeks via IV infusion or one of three chemotherapy drugspaclitaxel, docetaxel, or vinfluninegiven every three weeks by IV infusion. Treatment continues until the disease progresses or side effects become unacceptable. Rescue medications may be given as needed according to approved guidelines during treatment. During the trial, participants will have regular assessments including imaging to measure disease status and evaluations of side effects and quality of life. The main outcome measured is overall survival up to about 40 months, along with secondary outcomes like progression-free survival, response rates, duration of response, and changes in quality of life scores. Safety and adverse events will be monitored throughout, with the study lasting until April 2030.

Age: 18Years +All GendersPhase 3
111 locations
T

Actively Recruiting

Researchers are investigating a combination therapy of BNT326 and pumitamig for adults with advanced or metastatic non-small cell lung cancer NSCLC that has either relapsed, progressed, or is treatment-nafve. The study includes multiple parts to find the best dose levels, assess safety and tolerability, and evaluate how well the therapy works to shrink tumors in this patient population. The trial is open-label and conducted across multiple sites, focusing on participants with confirmed advanced NSCLC where no curative treatment is available. The study consists of three parts Part 1 focuses on finding safe dose combinations of BNT326 with pumitamig Part 2a expands the dose evaluation to examine preliminary effectiveness and safety and Part 2b randomizes participants to optimize dosing and assess the contribution of each therapy component. Participants with prior treatment and those who are treatment-nafve are enrolled in different cohorts. Treatment is administered via intravenous infusion, and dose levels for Part 2b are determined based on earlier results. Participants undergo a screening period before starting treatment, which can continue for up to 24 months or until disease progression or unacceptable side effects occur. Follow-up periods monitor safety, efficacy, and long-term survival, with total involvement expected to last about 36 months unless ongoing benefit warrants extended treatment. Researchers evaluate dose-limiting toxicities, adverse events, tumor response rates, progression-free survival, and pharmacokinetics to understand treatment effects and participant outcomes.

Age: 18Years +All GendersPhase 1Phase 2
86 locations
P

Actively Recruiting

Researchers are evaluating BG-C137, an antibody-drug conjugate targeting FGFR2b, in people with advanced solid tumors. This study aims to assess the safety, tolerability, how the drug moves and acts in the body, and early antitumor effects. It is a phase 1ab trial involving participants with tumors expressing FGFR2b or FGFR2 gene amplification who have received prior cancer treatments. The study is sponsored by BeOne Medicines and includes two main phases dose escalation and dose expansion. The trial has three parts Phase 1a evaluates increasing doses of BG-C137 alone and then in combination with other anticancer agents to establish safe dose levels. Phase 1b further explores the recommended dose in selected patient groups. BG-C137 and anticancer agents are given intravenously or orally depending on the treatment. Participants undergo dose escalation, safety expansions, and dose confirmations to determine the best dosing for further study. Participants will be monitored regularly for side effects and response to treatment for up to about two years. Assessments include measuring adverse events, drug levels in the blood, tumor response, and immune reactions to the drug. Safety follow-up visits occur after treatment ends. Researchers will measure outcomes such as maximum tolerated dose, overall response rate, disease control, and progression-free survival. The trial involves frequent visits for treatment and assessments throughout the study period.

Age: 18Years +All GendersPhase 1
52 locations
I

Actively Recruiting

This trial investigates BG-85738, a new experimental drug, in adults with advanced or metastatic solid tumors that have mutations in the RAS gene. It aims to evaluate the safety and effects of BG-85738 alone and in combination with other anticancer agents in patients whose cancer involves uncontrolled growth due to hyperactive RAS proteins. The study is conducted in two parts dose escalation to identify safe dosage levels, and dose expansion to study the drugs effects in more patients. Participants receive BG-85738 orally either by itself or combined with intravenous drugs tislelizumab or cetuximab. The dose escalation part tests ascending doses to find recommended levels without serious side effects. The dose expansion part treats participants with selected tumor types using the doses identified earlier, either as monotherapy or in combination with the other agents. The study involves multiple centers worldwide. Participants will visit clinics regularly over approximately 13 to 24 months for treatments and health monitoring. Assessments include blood tests, tumor imaging, and safety evaluations to track adverse events and drug effects. Researchers will measure outcomes such as response rates, progression-free survival, and drug levels over time. Safety is monitored up to 30 days after treatment ends, with ongoing follow-up to assess treatment impact and tolerability.

Age: 18Years +All GendersPhase 1
3 locations
I

Actively Recruiting

Researchers are evaluating the safety, tolerability, pharmacokinetics, and early antitumor activity of the drug BG-C0979 alone or combined with tislelizumab in adults with certain advanced solid tumors. This first-in-human study includes Phase 1a, focusing on dose escalation and safety expansion, and Phase 1b, which involves dose optimization and expansion. The study is sponsored by BeOne Medicines and aims to find safe and effective doses for future research. Participants will receive BG-C0979 through intravenous infusion. In Phase 1a, doses are gradually increased to find safe levels, followed by safety expansion at selected doses. In Phase 1b, participants receive optimized doses of BG-C0979 alone or in combination with tislelizumab for selected tumor types. The study includes multiple treatment groups, each with specific dosing plans and evaluation periods lasting up to approximately 24 months. During the study, participants will undergo regular assessments including imaging to measure tumor response, laboratory tests, and monitoring of side effects. Researchers will track drug levels in blood and evaluate measures like overall response rate, duration of response, disease control rate, and progression-free survival. This comprehensive monitoring will continue for up to two years to evaluate safety and preliminary effectiveness of the treatments.

Age: 18Years +All GendersPhase 1
18 locations
P

Actively Recruiting

Researchers are studying MEN2501, an oral drug, in adults with platinum-resistant ovarian cancer including high-grade serous ovarian cancer, primary peritoneal cancer, or fallopian tube cancer. This first-in-human, open-label trial aims to assess the safety, tolerability, how the drug moves through the body, its effects, and antitumor activity. The study is conducted in two parts dose escalation and dose expansionoptimization. In Part A, participants receive increasing doses of MEN2501 to evaluate dose-limiting toxicities during the first 28-day cycle. Part B focuses on determining the recommended phase 2 dose over approximately six months. The drug is given orally as tablets. The trial uses a sequential study model with randomized allocation and no masking. Participants will be monitored for treatment-emergent adverse events, tumor response rates, duration of response, clinical benefit, progression-free survival, overall survival, and drug concentration levels. These assessments occur over periods ranging from about six to twelve months. The total study duration extends to June 2028, with ongoing safety and efficacy follow-up through primary and secondary outcome measures.

Age: 18Years +FEMALEPhase 1
15 locations

1-10 of 169

1